Switzerland - Re-Imbursed Pharmaceutical Market
Since 2014, Switzerland Re-Imbursed Pharmaceutical Market rose 1.5points year on year. In 2019, the country was ranked number 12 comparing other countries in Re-Imbursed Pharmaceutical Market with 20.4 Percent of Generics in Value. Switzerland is overtaken by Denmark, which was number 11 with 21.5 Percent of Generics in Value and is followed by Netherlands at 19.7 Percent of Generics in Value. Austria topped the ranking with 52.2 Percent of Generics in Value in 2019, that is +2.8points compared to 2018. United Kingdom, Turkey and New Zealand respectively ranked number 2, 3 and 4 in this ranking. Denmark witnessed the best average annual growth at +6.9points per year, while Slovakia recorded the worst performance at -7.8points per year.
Loading...
Date | Percent of Generics in Value |
---|---|
2019 | 20.40 |
2018 | 20.10 |
2017 | 19.70 |
2016 | 19.30 |
2015 | 19.50 |
How does Switzerland rank in Re-Imbursed Pharmaceutical Market?
# | 17 Countries | Percent of Generics in Value | Last | YoY | 5‑years CAGR | ||
---|---|---|---|---|---|---|---|
1 |
#1
Austria
|
52.20 % | 2019 | +2.8 % | +2.2 % | View data | |
2 |
#2
United Kingdom
|
38.50 % | 2019 | +2.1 % | +2.6 % | View data | |
11 |
#11
Denmark
|
21.50 % | 2019 | +14.4 % | +6.9 % | View data | |
12 |
#12
Switzerland
|
20.40 % | 2019 | +1.5 % | +1.5 % | View data | |
13 |
#13
Netherlands
|
19.70 % | 2019 | -1.5 % | +3.6 % | View data |